Ensign Peak Advisors Inc Buys 265,389 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)

Ensign Peak Advisors Inc increased its position in shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 667.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 305,172 shares of the company's stock after acquiring an additional 265,389 shares during the quarter. Ensign Peak Advisors Inc owned about 0.18% of Revolution Medicines worth $13,348,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the company. IFP Advisors Inc acquired a new position in Revolution Medicines in the fourth quarter valued at about $34,000. Sterling Capital Management LLC lifted its stake in Revolution Medicines by 588.7% in the fourth quarter. Sterling Capital Management LLC now owns 1,956 shares of the company's stock valued at $86,000 after buying an additional 1,672 shares during the period. Farther Finance Advisors LLC lifted its stake in Revolution Medicines by 368.3% in the fourth quarter. Farther Finance Advisors LLC now owns 2,051 shares of the company's stock valued at $90,000 after buying an additional 1,613 shares during the period. Kapitalo Investimentos Ltda acquired a new position in Revolution Medicines in the fourth quarter valued at about $104,000. Finally, Daiwa Securities Group Inc. lifted its stake in Revolution Medicines by 521.8% in the fourth quarter. Daiwa Securities Group Inc. now owns 3,787 shares of the company's stock valued at $165,000 after buying an additional 3,178 shares during the period. Institutional investors and hedge funds own 94.34% of the company's stock.

Revolution Medicines Price Performance

Shares of Revolution Medicines stock traded up $0.10 during trading hours on Friday, hitting $39.54. The company's stock had a trading volume of 2,061,263 shares, compared to its average volume of 1,498,571. Revolution Medicines, Inc. has a 12 month low of $29.17 and a 12 month high of $62.40. The stock has a 50 day moving average of $37.49 and a 200 day moving average of $43.12. The company has a market capitalization of $7.37 billion, a PE ratio of -11.01 and a beta of 1.11.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($1.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.12) by ($0.01). During the same period last year, the company posted ($0.70) earnings per share. Equities analysts expect that Revolution Medicines, Inc. will post -3.49 EPS for the current year.

Analysts Set New Price Targets

RVMD has been the topic of several analyst reports. Stifel Nicolaus cut their target price on Revolution Medicines from $78.00 to $64.00 and set a "buy" rating on the stock in a research note on Tuesday, April 1st. HC Wainwright reissued a "buy" rating and issued a $72.00 target price (down previously from $73.00) on shares of Revolution Medicines in a research note on Wednesday. Needham & Company LLC reaffirmed a "buy" rating and set a $57.00 price objective on shares of Revolution Medicines in a research note on Thursday, May 8th. Wedbush reaffirmed an "outperform" rating and set a $67.00 price objective on shares of Revolution Medicines in a research note on Thursday, May 8th. Finally, Oppenheimer raised their price objective on Revolution Medicines from $70.00 to $75.00 and gave the stock an "outperform" rating in a research note on Thursday, May 8th. Twelve research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $67.08.

Insider Buying and Selling

In related news, insider Mark A. Goldsmith sold 11,738 shares of the stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $39.04, for a total transaction of $458,251.52. Following the completion of the transaction, the insider now directly owns 441,564 shares in the company, valued at approximately $17,238,658.56. This trade represents a 2.59% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Margaret A. Horn sold 3,058 shares of the stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $39.04, for a total value of $119,384.32. Following the transaction, the chief operating officer now owns 153,533 shares of the company's stock, valued at approximately $5,993,928.32. The trade was a 1.95% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 16,660 shares of company stock worth $650,406. 8.20% of the stock is owned by corporate insiders.

Revolution Medicines Company Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.